Daré Bioscience losses widen as cash runway raises concerns
Net loss expands to $13.4M as company prepares commercial launch of DARE to PLAY
Daré Bioscience reported a widening net loss of $13.4 million for the full year 2025, more than tripling the $4.05 million loss recorded in the prior year, as the San Diego-based biopharmaceutical company prepares for the commercial launch of its lead women's health product.
The company, which focuses on developing and marketing products for women's health, reported revenue of $1.03 million for 2025 — a minimal figure that nonetheless beat analyst expectations of near-zero revenue. The loss per share came in at $1.20, narrowing slightly from the previous year's $1.83 but still reflecting significant ongoing cash burn as the company transitions from clinical-stage development to commercial operations.
Perhaps most concerning for investors is Daré's cash position and working capital. As of December 31, 2025, the company held $24.7 million in cash and cash equivalents, but working capital stood at just $3.4 million. With the company now investing in commercial infrastructure for its upcoming product launch, analysts expect additional dilution may be required to fund operations through to profitability.
Daré's shares, which trade on the Nasdaq under the ticker DARE, have struggled amid these financial challenges. The stock closed at $1.51 on Thursday, trading below both its 50-day moving average of $1.71 and 200-day moving average of $2.09. Shares are down more than 50% from their 52-week high of $3.28 and are hovering near the year's low of $1.27. The company's market capitalization has dwindled to approximately $18.3 million.
Despite the stock's poor performance, analysts maintain an optimistic outlook. The consensus rating remains a "Strong Buy" with an average price target of $10.33, suggesting potential upside of more than 580% from current levels, according to market data compiled by TipRanks. Four analysts cover the stock, with three rating it a buy and one maintaining a strong buy rating. None have issued sell recommendations.
That bullish thesis rests largely on the commercial launch of DARE to PLAY™ Sildenafil Cream, the company's flagship product for women's sexual health. The company announced in December 2025 that prescription intake had begun through the DARE Health Hub, powered by Medvantx Pharmacy, initially in a limited number of states. By February 11, 2026, prescribing capabilities had expanded nationally to all 50 states, and telehealth access was launched to allow women to obtain prescriptions without in-person visits.
Sabrina Martucci Johnson, Daré's president and chief executive officer, sought to frame 2026 as a pivotal year for the company. "We are not a company that is just getting into women's health. We are a women's health biotech company — and we believe 2026 is the year investors will get to see what ten years of that commitment actually looks like," Johnson stated in the earnings announcement.
The company anticipates that actual dispensing of DARE to PLAY will commence in the coming months, with product revenue expected to begin in the second quarter of 2026. Simultaneously, Daré is advancing its sildenafil cream formulation through the FDA's 505(b)(2) NDA pathway, which could provide additional regulatory clarity and market positioning.
Johnson emphasized that the company's strategy is not reliant on a single product's success. "Daré is not a single-event binary bet. This is a portfolio with multiple potential catalysts, multiple pathways to value, and multiple ways to win," she said. "Every prescription written for DARE to PLAY builds the real-world dataset that will strengthen our future NDA submission."
However, the path from commercial launch to sustainable revenue remains uncertain. The company has yet to demonstrate significant revenue generation from any product, and the women's health market faces competitive pressures from both established pharmaceutical companies and emerging biotechnology firms.
Analysts at Trefis have previously rated Daré's overall financial health as "weak," highlighting concerns about the company's long-term stability given its continued net losses and unclear path to near-term profitability. The company's operating margin over the trailing twelve months was -1,623%, reflecting the intense capital requirements of its development and commercialization activities.
Investors will be closely watching the company's upcoming conference call, which was scheduled for Thursday afternoon, for additional details on commercialization strategy, potential partnership discussions, and updated guidance for cash burn rates through the critical launch period.